CRP and rectal cancer: Several proposed biomarkers are reported to predict response to neoadjuvant therapy in rectal cancer, yet none have entered routine practice because of problems with methodology and validation.35 Serum CRP and albumin, however, are widely used as markers of systemic inflammation.